Literature DB >> 15782689

[Direct reporting of side effects by the patient: favourable experience in the first year].

A C van Grootheest1, J L M Passier, E P van Puijenbroek.   

Abstract

OBJECTIVE: To determine the results of establishing a station at which patients can report the side effects of drugs.
DESIGN: Descriptive.
METHOD: Since 1 April 2003, patients may submit reports of possible adverse drug reactions directly to the Netherlands Pharmacovigilance Centre Lareb. The reports submitted during the period from 1 April 2003 to 31 March 2004 were analysed and compared with the reports submitted by doctors and pharmacists.
RESULTS: In the first year, 276 reports were submitted by patients and 3131 by doctors and pharmacists. The reports from patients usually contained sufficient medical information and more frequently referred to serious adverse reactions than reports by health professionals. The reports from patients relatively often concerned psychotherapeutic agents, notably antidepressants.
CONCLUSION: Based on the positive results during the first year, the Netherlands Pharmacovigilance Centre Lareb has decided to continue the reporting station for patients. Reports submitted by patients are currently part of the core responsibility of Lareb: the detection of signals of new adverse drug reactions.

Entities:  

Mesh:

Year:  2005        PMID: 15782689

Source DB:  PubMed          Journal:  Ned Tijdschr Geneeskd        ISSN: 0028-2162


  19 in total

Review 1.  Experiences with adverse drug reaction reporting by patients: an 11-country survey.

Authors:  Florence van Hunsel; Linda Härmark; Shanthi Pal; Sten Olsson; Kees van Grootheest
Journal:  Drug Saf       Date:  2012-01-01       Impact factor: 5.606

Review 2.  Patient reporting of suspected adverse drug reactions: a review of published literature and international experience.

Authors:  A Blenkinsopp; P Wilkie; M Wang; P A Routledge
Journal:  Br J Clin Pharmacol       Date:  2007-02       Impact factor: 4.335

3.  Consumer reporting of adverse drug reactions: a retrospective analysis of the Danish adverse drug reaction database from 2004 to 2006.

Authors:  Lise Aagaard; Lars Hougaard Nielsen; Ebba Holme Hansen
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

Review 4.  ADR Reporting by the General Public: Lessons Learnt from the Dutch and Swedish Systems.

Authors:  Linda Härmark; Florence van Hunsel; Birgitta Grundmark
Journal:  Drug Saf       Date:  2015-04       Impact factor: 5.606

5.  Community pharmacists' knowledge and perceptions about adverse drug reactions and barriers towards their reporting in Eastern region, Alahsa, Saudi Arabia.

Authors:  Tahir M Khan
Journal:  Ther Adv Drug Saf       Date:  2013-04

6.  Serious adverse events reported for antiobesity medicines: postmarketing experiences from the EU adverse event reporting system EudraVigilance.

Authors:  L Aagaard; C E Hallgreen; E H Hansen
Journal:  Int J Obes (Lond)       Date:  2016-08-01       Impact factor: 5.095

Review 7.  Pharmacovigilance: methods, recent developments and future perspectives.

Authors:  L Härmark; A C van Grootheest
Journal:  Eur J Clin Pharmacol       Date:  2008-06-04       Impact factor: 2.953

8.  Adverse drug reaction reporting by patients in the Netherlands: three years of experience.

Authors:  Joyce de Langen; Florence van Hunsel; Anneke Passier; Lolkje de Jong-van den Berg; Kees van Grootheest
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

9.  A qualitative study to explore how patients identify and assess symptoms as adverse drug reactions.

Authors:  Nataporn Chaipichit; Janet Krska; Thongchai Pratipanawatr; Verawan Uchaipichat; Narumol Jarernsiripornkul
Journal:  Eur J Clin Pharmacol       Date:  2014-02-16       Impact factor: 2.953

10.  Comparing patients' and healthcare professionals' ADR reports after media attention: the broadcast of a Dutch television programme about the benefits and risks of statins as an example.

Authors:  Florence van Hunsel; Anneke Passier; Kees van Grootheest
Journal:  Br J Clin Pharmacol       Date:  2009-02-26       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.